University of Michigan Researchers Develop Dual-Action Compound SH-273 to Combat Immunotherapy Resistance in Pancreatic Cancer

University of Michigan scientists develop SH-273, a dual-action drug overcoming immunotherapy resistance to improve pancreatic cancer survival outcomes.

By: AXL Media

Published: Apr 30, 2026, 9:49 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Precision Strike Against the Deadliest Oncological Shield

The persistent lethality of pancreatic ductal adenocarcinoma, which maintains a harrowing five-year survival rate of just 13 percent, has long been attributed to its ability to ignore the body's natural defenses. Current medical interventions remain stagnant with only two primary treatment regimens that offer marginal success against such an aggressive disease. According to researchers at the University of Michigan, the fundamental obstacle lies in the tumor's sophisticated immunotherapy resistance, a biological lockout that prevents the immune system from identifying and destroying malignant cells.

Decoding the Cellular Barriers of the Pancreatic Environment

The resistance mechanism within these tumors is not a single wall but a multi-layered defense system involving myeloid and regulatory B cells. These specific immune components effectively act as double agents, suppressing the very mechanisms intended to attack the cancer. Previous attempts to use STING agonists to wake up the immune system were met with a paradoxical reaction, while these agents successfully engaged myeloid cells, they inadvertently triggered an increase in regulatory B cells, which then halted the anti-tumor response.

The Molecular Logic of the SH-273 Breakthrough

To navigate this biological stalemate, a team led by Duxin Sun, a Professor of Pharmaceutical Sciences, focused on the specific enzyme PI3Kγ as the culprit behind the regulatory B cell surge. By identifying that myeloid activation could occur independently of this enzyme, the researchers were able to design SH-273 as a dual-targeting molecule. According to Sun, the strategic goal was to create a compound capable of adaptively stimulating beneficial immune pathways while simultaneously inhibiting the harmful ones that fuel resistance.